Medicure Inc. (OTCMKTS:MCUJF) Stock Short Interest Drops 93.1%

Medicure Inc. (OTCMKTS:MCUJF) saw a significant decline in short interest in the month of October. As of October 15th, there was short interest totaling 3,348 shares, a decline of 93.1% from the September 30th total of 48,345 shares. Based on an average trading volume of 26,042 shares, the days-to-cover ratio is currently 0.1 days. Approximately 0.0% of the shares of the company are short sold.

Medicure Price Performance

OTCMKTS:MCUJF traded up $0.16 during trading hours on Monday, reaching $3.16. The company had a trading volume of 18,534 shares, compared to its average volume of 14,800. The company has a current ratio of 0.97, a quick ratio of 0.64 and a debt-to-equity ratio of 0.02. Medicure has a 1-year low of $0.67 and a 1-year high of $3.45. The business’s 50 day moving average price is $1.97 and its 200-day moving average price is $1.11.

Medicure (OTCMKTS:MCUJF) last issued its quarterly earnings data on Friday, August 14th. The company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.05). The firm had revenue of $5.36 million for the quarter, compared to analyst estimates of $2.45 million. Medicure had a negative return on equity of 54.55% and a negative net margin of 23.14%.

About Medicure

Medicure Inc is a Canadian pharmaceutical company focused on developing and commercializing therapies for cardiovascular and related serious medical conditions. The company is headquartered in Winnipeg, Manitoba, and serves healthcare markets primarily through its U.S. pharmaceutical operations.

Medicure’s principal commercial product is AGGRASTAT (tirofiban hydrochloride), an intravenous antiplatelet medication used to help reduce thrombotic cardiovascular events in patients with acute coronary syndromes, including non-ST-segment elevation acute coronary syndrome.